An interventional study of Probiotic supplementation and Placebo in Healthy, Overweight (BMI > 25) and Overweight , Obesity, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Obesity by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Obesity · Maastricht University Medical Center.
Among the 75 studies in Obesity by Maastricht University Medical Center, this one is the 5th largest by planned enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2026, is one of 65 with no phase, and was the 74th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →4 of the 75 studies in Obesity by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 60–80 · Healthy volunteers
Maastricht University Medical Center · Sites in Netherlands
Ages 40–75 · Healthy volunteers
Maastricht University Medical Center · Sites in Netherlands
Ages 40–75
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 40 across the 67 interventional studies, 91 across the 8 observational. Of the 60 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
2 of the studies in Obesity by Maastricht University Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923644Maastricht University Medical CenterTargeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases | 2027-04 |
| NCT07395973Maastricht University Medical CenterThe Effects of a 4-week Supplementation With a Ketogenic Nutrient Mix on 24-hour Substrate Metabolism and Muscle Health | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies in Obesity by Maastricht University Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this 16-week randomised, placebo-controlled parallel study is to investigate the effect of a newly formed probiotic supplement on satiety and gut microbiota composition in healthy men and women with overweight or obesity form 20-70 years old. The main question it aims to answer is:
Does the probiotic supplement increase feelings of satiety and alter gut microbiota composition?
Participants will:
Rationale: Satiety hormones, including glucagon-like peptide-1 (GLP-1), are key regulators of food intake. Deficiencies in the release of satiety hormones as well as alterations in the composition and the function of the gut microbiota are hallmarks of overweight and obesity. Probiotics can improve the overall structure of the gut microbiota, and show strain-specific differences with regard to their ability to stimulate satiety hormones. Those animal-based findings, if confirmed in human studies, may pose a gateway for decreased food intake, weight management, and ultimately weight loss. The investigators hypothesise that a newly developed combination of probiotic strains, specifically selected for their potential to (in vitro) influence pathways related to weight management, will decrease food intake through increased release of satiety hormones (i.e. GLP-1) and beneficial alteration of the gut microbiota in humans.
Objective: The primary objective of the study is to investigate the effects of a combination of specifically selected probiotic strains in a new probiotic formulation on ad libitum food intake, in individuals with overweight and/or obesity. The investigators will address this objective firstly with an acute study followed by a proof-of-concept 4-months intervention study comparing a total of 98 individuals in a 16-week randomised, placebo-controlled parallel study (49 participants probiotic/ 49 participants placebo).
Study design: This intervention study will have a randomised, controlled parallel design. The total study duration will be 16 weeks.
Study population: A total of 98 men and women between the ages of 20-70 years old, with overweight/obesity (BMI: 26-40 kg/m2) will be recruited, accounting for a drop-out rate of 20%.
Intervention: Study participants will receive a daily dose of 6 g probiotic supplement (packed in sachets of 3 g) or placebo for 16 weeks.
Main study parameters/endpoints: At baseline and after 16 weeks, participants will visit the research facilities for assessments. The primary endpoint is the difference in satiety measured by ad libitum food intake comparing the probiotic and control intervention. Secondary outcome parameters are related to changes in satiety hormones (including GLP-1), fecal microbiota analysis, insulin sensitivity (HOMA-IR), inflammatory markers and lipid metabolism.
Exploratory outcomes concern perceived satiety, body composition and mental health. This study will provide insight into the potential beneficial effect of a newly composed probiotic supplement on satiety in overweight/obese adults.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 98 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6g of probiotic supplement daily
Dietary Supplement: Probiotic supplementation
6g of placebo daily
Other: Placebo
16-week consumption of 6 g/day of probiotic supplement
16-week consumption of 6 g/day of placebo
Ad libitum food intake
The primary objective of the study is to investigate the effects of a combination of specifically selected probiotic strains in a new probiotic formulation on ad libitum food intake, in individuals with overweight and/or obesity. The primary endpoint is the difference in satiety measured by ad libitum food intake comparing the probiotic and control intervention.
Time frame: From enrolment to the end of the 16-week intervention
Satiety hormones
Satiety hormones, GLP-1, PYY, and ghrelin, will be measured in the blood by taking fasted and postprandial blood samples at multiple timepoints.
Time frame: From enrolment to the end of the 16-week intervention
Subjective Appetite Sensation
Visual Analogue Scales (VAS) will be used to register different aspects of appetite, thirst, and well-being during the test days. The questions concern hunger, satiety, fullness, thirst, prospective food consumption, and desire to eat. Using a validated, 100-mm line, participants place a mark on the line between anchors like "not at all" (0 mm) and "extremely" (100 mm). Appetite sensation will be assessed at 30-minute intervals starting at time -30 until the ad libitum lunch for a total of 240 minutes.
Time frame: From enrolment to the end of the 16-week intervention
Fecal microbial composition
Stool samples will be collected at home and immediately stored in the freezer at -20°C. Participants will bring the stool sample to the laboratory, while preserving the cold chain, where samples will be kept in a -80°C freezer until further analysis. We will profile the gut microbiota composition at baseline and after treatment using 16S rRNA gene amplicon sequencing techniques. Sequencing data will be processed using our validated in-house Bio-IT pipeline and microbial richness, diversity, community structure and taxonomic composition will be linked to the probiotic intervention as well as treatment outcomes.
Time frame: From enrolment to the end of the 16-week intervention
Diet
Participants will be instructed to continue their usual dietary pattern throughout the intervention period to study the isolated effect of probiotic supplementation. Before, at week 8 and in the last week of the intervention period, participants' dietary pattern will be assessed by means of a FFQ.
Time frame: From enrolment to the end of the 16-week intervention
Physical Activity
Participants will be instructed to continue their usual physical activity pattern throughout the intervention period to study the isolated effect of probiotic supplementation. Before, at week 8 and in the last week of the intervention period, participants' physical acitivity pattern will be assessed by means of the SQUASH questionnaire.
Time frame: From enrolment to the end of the 16-week intervention
Insulin resistance
Fasted blood samples for glucose and insulin will be taken to determine the homeostatic model assessment of insulin resistance (HOMA-IR) and beta-cell function.
Time frame: From enrolment to the end of the 16-week intervention
Blood pressure
Office BP (SBP and DBP) will be determined in four-fold (the first measurement will be discarded, and the last three measurements will be averaged) using a semi continuous blood pressure monitoring device (Omron M7, CEMEX Medische Techniek, Nieuwegein, The Netherlands).
Time frame: From enrolment to the end of the 16-week intervention
Heart rate
Heart rate (HR) will be determined in four-fold (the first measurement will be discarded, and the last three measurements will be averaged) using a semi continuous blood pressure monitoring device (Omron M7, CEMEX Medische Techniek, Nieuwegein, The Netherlands).
Time frame: From enrolment to the end of the 16-week intervention
Lipids
Fasting and postprandial serum triacylglycerol (TAG) and total cholesterol (TC) and HDL-C concentrations will be measured.
Time frame: From enrolment to the end of the 16-week intervention
Inflammatory markers
Plasma markers related to systemic inflammation will be measured in the blood to assess low-grade systemic inflammatory responses.
Time frame: From enrolment to the end of the 16-week intervention
Body Composition
Measurement of body composition is done by BodPod in a fasted state.
Time frame: From enrolment to the end of the 16-week intervention
Anthropometric measurements - Body weight
Body weight will be measured in kilograms before the measurements without shoes and heavy clothing.
Time frame: From enrolment to the end of the 16-week intervention
Anthropometric measurements - length
Length will be measured in centimeters before the measurements without shoes and heavy clothing.
Time frame: From enrolment to the end of the 16-week intervention
Anthropometric measurements - waist and hip circumferences
Waist and hip circumferences will be measured in centimeters before the measurements using a SECA tape measure
Time frame: From enrolment to the end of the 16-week intervention
Mental health
Mental health will be assessed using the validated Beck Depression (BDI) and State-Trait Anxiety Inventories (STAI).
Time frame: From enrolment to the end of the 16-week intervention
Mood
Mood will be tested using the widely-applied Profile of Mood States (POMS).
Time frame: From enrolment to the end of the 16-week intervention
Stress
Stress will be assessed using the Perceived Stress Scale (PSS).
Time frame: From enrolment to the end of the 16-week intervention
Sleep characteristics
Sleep characteristics will be assessed at the end of the interventions using the Pittsburgh Sleep Quality Index (PSQI).
Time frame: From enrolment to the end of the 16-week intervention
Cognitive restrained
Cognitive restrained, disinhibition and hunger will be assessed using the Dutch three factor eating questionnaire
Time frame: From enrolment to the end of the 16-week intervention
Disinhibition
Cognitive restrained, disinhibition and hunger will be assessed using the Dutch three factor eating questionnaire
Time frame: From enrolment tot he end of the 16-week intervention
Hunger
Cognitive restrained, disinhibition and hunger will be assessed using the Dutch three factor eating questionnaire
Time frame: From enrolment tot he end of the 16-week intervention
Quality of life assessment
The quality of life will be assessed at the end of the interventions using a 32-item questionnaire. This measure will quantify quality of life on different dimensions: social, spiritual, emotional, cognitive, physical, activities of daily living, and integrated quality of life.
Time frame: From enrolment to the end of the 16-week intervention
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Mar 2026 (actual). Primary completion is estimated for Aug 2029, 41 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 41 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →